Sustained miRNA-mediated Knockdown of Mutant AAT With Simultaneous Augmentation of Wild-type AAT Has Minimal Effect on Global Liver miRNA Profiles

Department of Pediatrics and Gene Therapy Center, UMass Medical School, Worcester, Massachusetts 01605, USA.
Molecular Therapy (Impact Factor: 6.23). 03/2012; 20(3):590-600. DOI: 10.1038/mt.2011.292
Source: PubMed


α-1 antitrypsin (AAT) deficiency can exhibit two pathologic states: a lung disease that is primarily due to the loss of AAT's antiprotease function, and a liver disease resulting from a toxic gain-of-function of the PiZ-AAT (Z-AAT) mutant protein. We have developed several recombinant adeno-associated virus (rAAV) vectors that incorporate microRNA (miRNA) sequences targeting the AAT gene while also driving the expression of miRNA-resistant wild-type AAT-PiM (M-AAT) gene, thus achieving concomitant Z-AAT knockdown in the liver and increased expression of M-AAT. Transgenic mice expressing the human PiZ allele treated with dual-function rAAV9 vectors showed that serum PiZ was stably and persistently reduced by an average of 80%. Treated animals showed knockdown of Z-AAT in liver and serum with concomitant increased serum M-AAT as determined by allele-specific enzyme-linked immunosorbent assays (ELISAs). In addition, decreased globular accumulation of misfolded Z-AAT in hepatocytes and a reduction in inflammatory infiltrates in the liver was observed. Results from microarray studies demonstrate that endogenous miRNAs were minimally affected by this treatment. These data suggests that miRNA mediated knockdown does not saturate the miRNA pathway as has been seen with viral vector expression of short hairpin RNAs (shRNAs). This safe dual-therapy approach can be applied to other disorders such as amyotrophic lateral sclerosis, Huntington disease, cerebral ataxia, and optic atrophies.

Download full-text


Available from: Christian Mueller
  • Source
    • "ess - ing of the miRNA from the RHO transcript is likely to reduce the level of mature mRNA either by interfering with splicing or polyadenylation . Nevertheless , delivery of artificial miRNAs with a resistant replacement gene has been success - fully employed in a mouse model of liver failure associated with the PiZ allele of a - 1 antitrypsin ( Mueller et al . 2012 ) . O ' Reilly and colleagues attempted the RNA replacement approach in transgenic mice bear - ing a P23H RHO gene with limited success ( O ' Reilly et al . 2007 ) . Their AAV serotype 5 vec - tor contained a pol III promoter driving the expression of an shRNA that they showed to be effective in suppressing human rhodopsin mRNA in trans"
    [Show abstract] [Hide abstract]
    ABSTRACT: Mutations in the gene for rhodopsin, RHO, cause autosomal dominant retinitis pigmentosa, a disease characterized by death of rod photoreceptor cells. At the end stage, when most rods are gone, cones die too, taking central vision with them. One goal of gene therapy, therefore, is to preserve central vision by promoting rod survival in the vicinity of the macula. Dominance in RHO mutations is associated with two phenomena: interference with the function of normal rhodopsin and intrinsic toxicity of the mutant protein. In the case of interference, increased production of the wild-type protein may be therapeutic, but in the case of toxicity, suppression of the mutant protein may also be needed. RHO augmentation has made use of advances in gene delivery to the retina using adeno-associated virus (AAV). Several strategies have been developed for suppression of rhodopsin expression, but because of the heterogeneity of RHO mutations they are not specific for the mutant allele: They suppress both mutant and wild-type RHO. Experiments in autosomal dominant retinitis pigmentosa (adRP) mouse models suggest that both RHO augmentation and supplementation plus suppression preserve the survival of rod cells.
    Full-text · Article · Jul 2014 · Cold Spring Harbor Perspectives in Medicine
  • Source
    • "Since functional coupling between intermediates of the RNAi pathway may occur, expression of earlier intermediates of the RNAi pathway, such as pri-miRs, may improve efficiency of target silencing. Moreover, use of artificial pri-miR cassettes that are expressed from Pol II promoters has been shown to be safer than employing U6 Pol III shRNA expression cassettes [11, 13–15]. Use of a liver-specific promoter to express anti-HBV sequences is also potentially useful to limit nonspecific effects that may be caused by constitutively active transcriptional regulatory elements. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Research on applying RNA interference (RNAi) to counter HBV replication has led to identification of potential therapeutic sequences. However, before clinical application liver-specific expression and efficient delivery of these sequences remain an important objective. We recently reported short-term inhibition of HBV replication in vivo by using helper dependent adenoviral vectors (HD Ads) expressing anti-HBV sequences from a constitutively active cytomegalovirus (CMV) promoter. To develop the use of liver-specific transcription regulatory elements we investigated the utility of the murine transthyretin (MTTR) promoter for expression of anti-HBV primary microRNAs (pri-miRs). HD Ads containing MTTR promoter effected superior expression of anti-HBV pri-miRs in mice compared to HD Ads containing the CMV promoter. MTTR-containing HD Ads resulted in HBV replication knockdown of up to 94% in mice. HD Ads expressing trimeric anti-HBV pri-miRs silenced HBV replication for 5 weeks. We previously showed that the product of the codelivered lacZ gene induces an immune response, and the duration of HBV silencing in vivo is likely to be attenuated by this effect. Nevertheless, expression of anti-HBV pri-miRs from MTTR promoter is well suited to countering HBV replication and development of HD Ads through attenuation of their immunostimulatory effects should advance their clinical utility.
    Full-text · Article · Jun 2014 · BioMed Research International
  • Source
    • "The latter joins to the canonical pathway from various branches (Fig. 2). For example, mirtrons (short intronic microRNA) (Parsi et al. 2012; Gokhale et al. 2012; Yan et al. 2011) and simtrons (splicingindependent mirtron-like miRNAs) (Havens et al. 2012; Curtis et al. 2012), shRNAs (short hairpin RNA) (Mueller et al. 2012; Dallas et al. 2012), snoRNAs (small nucleolar RNAs) (Scott and Ono 2011; Ono et al. 2011), and tRNAs (Schopman et al. 2010; Lee et al. 2009) which will be discussed in more details may join as alternative pathways to pri-miRNA/pre-miRNA steps (Fig. 1). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Understanding gene regulation mechanisms has been a serious challenge in biology. As a novel mechanism, small non-coding RNAs are an alternative means of gene regulation in a specific and efficient manner. There are growing reports on regulatory roles of these RNAs including transcriptional gene silencing/activation and post-transcriptional gene silencing events. Also, there are several known small non-coding RNAs which all work through RNA interference pathway. Interestingly, these small RNAs are secreted from cells toward targeted cells presenting new communication approach in cell-cell or cell-organ signal transduction. In fact, understanding cellular and molecular basis of these pathways will strongly improve developing targeted therapies and potent and specific regulatory tools. This study will review some of the most recent findings in this subject and will introduce a super-pathway RNA interference-based small RNA silencing network.
    Full-text · Article · Nov 2013 · Functional & Integrative Genomics
Show more